RECENT NEWS
03/29/18
Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering
03/13/18
Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline
02/12/18
Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an...
 
 
© 2015 Pulmatrix, Inc. All Rights Reservedhome   about pulmatrix   platform   pipeline   investors   careers   contact   site design